Suppr超能文献

在 Medicare 受益人群中,患有阿尔茨海默病和相关痴呆症的患者中,药物治疗管理项目的入组存在种族/民族差异。

Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.

机构信息

Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA.

Department of Preventive Medicine, University of Tennessee Health Science Center College of Medicine, Memphis, TN, USA.

出版信息

Curr Med Res Opin. 2022 Oct;38(10):1715-1725. doi: 10.1080/03007995.2022.2103962. Epub 2022 Aug 9.

Abstract

OBJECTIVE

Previous analysis of policy scenarios reported potential disparities in eligibility in the Medicare Medication Therapy Management (MTM) program. With recently released MTM data, this study aimed to determine if racial/ethnic disparities exist in MTM enrollment among Medicare beneficiaries with Alzheimer's disease and related dementias (ADRD).

METHODS

Medicare claims/records (from 2013-2014 and 2016-2017) linked to the Area Health Resources File were examined. Included individuals were patients with ADRD and diabetes, hypertension or hyperlipidemia. The proportions of MTM enrollment were compared between non-Hispanic White (White) patients and racial/ethnic minority groups in descriptive analysis. Racial/ethnic disparities were then examined using a logistic regression adjusting for patient and community characteristics. Disparities across study periods were compared by estimating a logistic regression model with interaction terms between dummy variables for each racial/ethnic minority group and 2016-2017.

RESULTS

In unadjusted analyses, minorities had higher enrollment proportions than Whites. In 2016-2017, for example, enrollment percentages for Whites, Blacks, Hispanics, Asian/Pacific Islanders (Asians) and Others were respectively 14.44%, 16.71%, 19.83%, 16.66%, and 17.78%. In adjusted analyses, Blacks had lower enrollment odds than Whites within all cohorts. In the entire study sample in 2016-2017, for example, Blacks with ADRD had 9% lower odds of MTM enrollment (odds ratio 0.91, 95% confidence interval [CI] = 0.86-0.97) than Whites. These disparities decreased over time among the ADRD sample and all sub-groups. The interaction term between Blacks and 2016-2017, for instance, indicated that disparities were lowered by 11% (odds ratio 1.11, 95% CI = 1.05-1.16) across study periods among those with ADRD.

CONCLUSIONS

Blacks with ADRD, and diabetes, hypertension or hyperlipidemia have lower likelihood of MTM enrollment than Whites. Racial disparities were reduced over time but not eliminated.

摘要

目的

之前对政策方案的分析报告称,在医疗保险药物治疗管理(MTM)计划中,资格认定存在差异。随着最近发布的 MTM 数据,本研究旨在确定在 Medicare 受益人群中,患有阿尔茨海默病和相关痴呆症(ADRD)的患者中,是否存在 MTM 注册方面的种族/民族差异。

方法

对 2013-2014 年和 2016-2017 年的医疗保险索赔/记录(与地区卫生资源文件相关联)进行了检查。纳入的患者为患有 ADRD 以及糖尿病、高血压或高血脂的患者。在描述性分析中,比较非西班牙裔白人(白人)患者和少数族裔群体之间 MTM 注册比例。使用调整患者和社区特征的逻辑回归来检查种族/民族差异。通过估计 2016-2017 年每个少数族裔群体和虚拟变量之间的交互项的逻辑回归模型来比较研究期间的差异。

结果

在未调整的分析中,少数民族的注册比例高于白人。例如,在 2016-2017 年,白人、黑人、西班牙裔、亚洲/太平洋岛民(亚洲人)和其他人的注册百分比分别为 14.44%、16.71%、19.83%、16.66%和 17.78%。在调整分析中,在所有队列中,黑人的注册几率均低于白人。例如,在整个研究样本中,患有 ADRD 的黑人参加 MTM 的几率比白人低 9%(优势比 0.91,95%置信区间[CI] = 0.86-0.97)。在 ADRD 样本以及所有亚组中,这些差异随时间而减少。例如,黑人与 2016-2017 年之间的交互项表明,在患有 ADRD 的人群中,差异降低了 11%(优势比 1.11,95%CI = 1.05-1.16)。

结论

患有 ADRD、糖尿病、高血压或高血脂的黑人参加 MTM 的可能性低于白人。种族差异随时间减少,但并未消除。

相似文献

5
Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population.
Res Social Adm Pharm. 2014 Nov-Dec;10(6):904-917. doi: 10.1016/j.sapharm.2014.02.007. Epub 2014 Mar 2.
6
Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria.
Res Social Adm Pharm. 2014 Jan-Feb;10(1):106-25. doi: 10.1016/j.sapharm.2013.03.007. Epub 2013 Jun 10.
8
Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.
J Asthma. 2017 Jun;54(5):504-513. doi: 10.1080/02770903.2016.1238927. Epub 2016 Sep 27.
9
Historical trend of disparity implications of Medicare MTM eligibility criteria.
Res Social Adm Pharm. 2013 Nov-Dec;9(6):758-69. doi: 10.1016/j.sapharm.2012.09.003. Epub 2012 Oct 10.
10
Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population.
J Am Pharm Assoc (2003). 2012 Sep-Oct;52(5):e87-96. doi: 10.1331/JAPhA.2012.11146.

引用本文的文献

1
Receipt of Medicare Part D comprehensive medication reviews in older adults with dementia.
J Manag Care Spec Pharm. 2025 Mar;31(3):296-305. doi: 10.18553/jmcp.2025.31.3.296.
3
Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.
J Manag Care Spec Pharm. 2024 Jun;30(6):609-616. doi: 10.18553/jmcp.2024.30.6.609.
4
Inherent Bias in Electronic Health Records: A Scoping Review of Sources of Bias.
medRxiv. 2024 Apr 12:2024.04.09.24305594. doi: 10.1101/2024.04.09.24305594.
5
Mapping racial and ethnic healthcare disparities for persons living with dementia: A scoping review.
Alzheimers Dement. 2024 Apr;20(4):3000-3020. doi: 10.1002/alz.13612. Epub 2024 Jan 24.

本文引用的文献

1
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
Alzheimers Dement. 2021 Dec;17(12):1966-1975. doi: 10.1002/alz.12362. Epub 2021 May 27.
2
Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease.
Curr Med Res Opin. 2021 Sep;37(9):1581-1588. doi: 10.1080/03007995.2021.1935224. Epub 2021 Jun 24.
3
2021 Alzheimer's disease facts and figures.
Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23.
4
Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.
6
Patterns and predictors of older adult Medicare Part D beneficiaries' receipt of medication therapy management.
Res Social Adm Pharm. 2020 Sep;16(9):1208-1214. doi: 10.1016/j.sapharm.2019.12.007. Epub 2019 Dec 9.
8
Comparison of Medication Therapy Management Services and Their Effects on Health Care Utilization and Medication Adherence.
J Manag Care Spec Pharm. 2019 Jun;25(6):688-695. doi: 10.18553/jmcp.2019.25.6.688.
9
Racial and ethnic disparities in medication adherence among privately insured patients in the United States.
PLoS One. 2019 Feb 14;14(2):e0212117. doi: 10.1371/journal.pone.0212117. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验